Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · §4

Metabolic dysfunction-associated steatohepatitis — compounds assessed

The 5 compounds the Institute assesses in metabolic dysfunction-associated steatohepatitis.

Document identifier
CEI-IN-05/4
Series
Indication assessment
Version
1.0
Published
18 Jan 2025
Last reviewed
18 Jan 2025
Next review
18 Jan 2027
Identifier
10.71829/cei.ind.5
Certainty
Not rated
Cycle
2025 Q1
ICD-11
DB92.1
Category
Hepatic

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

  • GLP-1 receptor agonist (acylated, long-acting)1 contributing trialfull monograph

    Resolution of steatohepatitis without worsening of fibrosis in 62.9 % versus 34.3 % with placebo at 72 weeks — Part 1 of a two-part trial; the clinical-outcome part had not reported at this assessment cycle.

    Moderate
  • Triple GIP, GLP-1 and glucagon receptor agonist (acylated)1 contributing trialfull monograph

    Liver-fat reduction exceeding 80 % relative at higher doses in a phase 2 imaging substudy — Imaging surrogate only; no histological endpoint reported.

    Low
  • Dual glucagon and GLP-1 receptor agonist (acylated)2 contributing trialsfull monograph

    Histological improvement in fibrosis without worsening of steatohepatitis in 34.5 % at 4.8 mg versus 22.4 % with placebo at 48 weeks — Phase 2 with a paired-biopsy endpoint in a modest sample; the fibrosis result is hypothesis-generating.

    Low
  • Growth-hormone-releasing hormone analogue1 contributing trialfull monograph

    Liver fat fraction reduced by 4.1 percentage points versus 0.9 with placebo at 12 months in people with HIV and hepatic steatosis — Small single trial in a specific population.

    Low
  • Dual GIP and GLP-1 receptor agonist (acylated)1 contributing trialfull monograph

    Resolution of steatohepatitis without worsening fibrosis in 44–62 % across doses versus 10 % with placebo at 52 weeks — Phase 2 only, wide confidence limits, no phase 3 histological result at this cycle.

    Low

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.